SAN DIEGO, March 14 /PRNewswire-FirstCall/ -- Somaxon Pharmaceuticals, Inc. today announced that it will release its 2005 financial results after the market closes on Tuesday, March 21, 2006. Somaxon management will host a conference call that same afternoon at 4:30 p.m. EST (1:30 p.m. PST) to review the financial results and answer questions.
The conference call will be available to interested parties through a live audio Internet broadcast at www.somaxon.com and www.opencompany.info. The call will also be archived and accessible at both sites for one year. Alternatively, callers may participate in the conference call by dialing (800) 811-0667 (domestic) or (913) 981-4901 (international), and entering passcode 7420782. A telephonic replay will be available for approximately one week following the conclusion of the call by dialing (888) 203-1112 (domestic) or (719) 457-0820 (international), and entering passcode 7420782.
About Somaxon Pharmaceuticals, Inc.
Headquartered in San Diego, California, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR(TM) (doxepin hydrochloride), is in Phase III clinical trials for the treatment of insomnia.
Contacts:
Investors, please contact Meg McGilley, Chief Financial Officer, (858) 509-3670, or Rob Whetstone, PondelWilkinson, Inc., (310) 279-5980, or visit the company's website at www.somaxon.com.
Somaxon Pharmaceuticals, Inc.CONTACT: Meg McGilley, Chief Financial Officer of Somaxon Pharmaceuticals,Inc., +1-858-509-3670; or Rob Whetstone of PondelWilkinson, Inc.,+1-310-279-5980, for Somaxon Pharmaceuticals, Inc.
